Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 9 of 9 for “"MDC1A"”.
-
Enhanced alpha7beta1 integrin prevents muscle disease in a mouse model of congenital muscular dystrophy
… Deficient Congenital Muscular Dystrophy Type 1A (MDC1A) is the most common form of Congenital Muscular Dystrophy (CMD). MDC1A accounts for approximately 40% of all CMD cases. CMD is estimated to have an incidence rate in the United States of 1/100,000 live births. MDC1A is a lethal disease which …
-
Efficacy of losartan and growth hormone combinatorial therapy in DyW mice
Merosin-deficient CMD type 1A (MDC1A) is the second most common form of congenital muscular dystrophy (CMD) that presents at or near birth. MDC1A is caused by a mutation in the LAMA2 gene which encodes a protein called laminin-2. The clinical manifestations of MDC1A include profound muscle …
-
Congenital muscular dystrophy with laminin α2 chain-deficiency. Initiation of disease and development of treatment
Congenital muscle dystrophy type 1A (MDC1A) is a muscle disease caused bymutations in the LAMA2 gene, encoding the basement membrane protein lamininα2 chain. MDC1A patients exhibit neonatal onset of muscle weakness, progressivemuscle wasting and hypotonia, joint contractures that mostly affect …
-
A New Congenital Mouse Model to Study Laminin Protein Therapy for Muscular Dystrophy
… deficient congenital muscular dystrophy type 1A (MDC1A) is caused by the loss of laminin-211 and laminin-221 heterotrimers which are most abundant in skeletal and cardiac muscle basal lamina; mutations in the LAMA2 gene cause the loss of these laminin isoforms. This absence of laminin-211/221 in …
-
Congenital muscular dystrophy: early pathology and combinatorial treatment strategies
MDC1A, the second most prevalent form of congenital muscular dystrophy, is an aggressive disease characterized by severe muscle weakness, hypotonia, contractures, spinal deformities, and premature death due to respiratory complications or failure to thrive. MDC1A results from mutation of the LAMA2 …
-
Laminin-111 Protein Therapy for the Treatment of Merosin Deficient Congenital Muscular Dystrophy Type 1A
… congenital muscular dystrophy type 1A (MDC1A) is a serious neuromuscular disease caused by a mutant LAMA2 gene. Loss of function of the LAMA2 gene leads to a deficiency of laminin-211/221, which are crucial to the basal lamina and the integrity of skeletal muscle. Currently, there is no …
-
Cerebellar synaptic plasticity in two animal models of muscular dystrophy
… (DMD) and congenital muscular dystrophy 1A (MDC1A) are the two most common forms of muscular dystrophy in humans, caused by mutations in dystrophin and laminin α2 genes respectively. Both are severe forms of the disease that lead to premature death due and are both now known to have a …
-
Characterizing and targeting fibrosis in a model of Lama2-related muscular dystrophy
… congenital muscular dystrophy 1A (MDC1A) is the second most prevalent congenital muscular dystrophy (CMD) and is due to a defect in the alpha chain of the basement membrane protein laminin-211. This protein serves as the vital link between the muscle cell membrane (sarcolemma) and …
-
Protein Therapy for Muscular Dystrophy and Other Muscle Diseases
Despite the exponential advancements in understanding the underlying cause of muscular diseases, there has been little progress in developing an effective treatment which results in the quality of life treatment options desperately needed for patients and families. The muscular dystrophies are a …